GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Rani Therapeutics Holdings Inc (NAS:RANI) » Definitions » Forward PE Ratio

Rani Therapeutics Holdings (Rani Therapeutics Holdings) Forward PE Ratio : 0.00 (As of Apr. 30, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Rani Therapeutics Holdings Forward PE Ratio?

Rani Therapeutics Holdings's Forward PE Ratio for today is 0.00.

Rani Therapeutics Holdings's PE Ratio without NRI for today is 0.00.

Rani Therapeutics Holdings's PE Ratio for today is 0.00.


Rani Therapeutics Holdings Forward PE Ratio Historical Data

The historical data trend for Rani Therapeutics Holdings's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rani Therapeutics Holdings Forward PE Ratio Chart

Rani Therapeutics Holdings Annual Data
Trend
Forward PE Ratio

Rani Therapeutics Holdings Quarterly Data
Forward PE Ratio

Competitive Comparison of Rani Therapeutics Holdings's Forward PE Ratio

For the Biotechnology subindustry, Rani Therapeutics Holdings's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Rani Therapeutics Holdings's Forward PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Rani Therapeutics Holdings's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where Rani Therapeutics Holdings's Forward PE Ratio falls into.



Rani Therapeutics Holdings Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.


Rani Therapeutics Holdings  (NAS:RANI) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .


Rani Therapeutics Holdings Forward PE Ratio Related Terms

Thank you for viewing the detailed overview of Rani Therapeutics Holdings's Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Rani Therapeutics Holdings (Rani Therapeutics Holdings) Business Description

Traded in Other Exchanges
N/A
Address
2051 Ringwood Avenue, San Jose, CA, USA, 95131
Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics. The company has developed the RaniPill capsule, a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing.
Executives
Talat Imran director, officer: CEO C/O RANI THERAPEUTICS HOLDINGS, INC., 2051 RINGWOOD AVENUE, SAN JOSE CA 95131
South Cone Investments Limited Partnership 10 percent owner AVENIDA PRESIDENTE RIESCO 5711 OFICINA 1, LAS CONDES, SANTIAGO F3 7550000
Quiroga Cortes Isidoro Alfonso 10 percent owner 9020 N CAPITAL OF TEXAS HWY, SUITE I-260, AUSTIN TX 78759
Jean Luc Butel director ONE BAXTER PARKWAY, DEERFIELD IL 60015
Maulik Nanavaty director BOSTON SCIENTIFIC CORPORATION, 300 BOSTON SCIENTIFIC WAY, MARLBOROUGH MA 01752-1234
Kate Mckinley officer: CHIEF BUSINESS OFFICER C/O RANI THERAPEUTICS HOLDINGS, INC., 2051 RINGWOOD AVE., SAN JOSE CA 95131
Svai S Sanford officer: CFO C/O RANI THERAPEUTICS LLC, 2051 RINGWOOD AVE., SAN JOSE CA 95131
Eric Groen officer: General Counsel C/O RANI THERAPEUTICS HOLDINGS, INC., 2051 RINGWOOD AVE., SAN JOSE CA 95131
Mir Hashim officer: Chief Scientific Officer C/O RANI THERAPEUTICS HOLDINGS, INC., 2051 RINGWOOD AVENUE, SAN JOSE CA 95131
South Lake One Llc 10 percent owner 250 WEST 55TH STREET, NEW YORK NY 10019
Aequanimitas Limited Partnership 10 percent owner LEONEL AGUIRRE 1830, UNIT 101, MONTEVIDEO X3 11500
Mir A Imran director
Andrew Farquharson director C/O RANI THERAPEUTICS HOLDINGS, INC., 2051 RINGWOOD AVENUE, SAN JOSE CA 95131
Laureen Debuono director
Lisa Ann Rometty director C/O RANI THERAPEUTICS HOLDINGS, INC., 2051 RINGWOOD AVE., SAN JOSE CA 95131